ClinicalTrials.gg
RecruitingNCT07714018Updated Oct 16, 2026

Comparing Two Weight Loss Programs for the Prevention of Kidney Cancer Progression Among Patients With Small Renal Masses on Active Surveillance

An interventional study of Intermittent Fasting and Continuous Energy Restriction (CER) in Renal Cell Carcinoma (RCC), sponsored by Roswell Park Cancer Institute. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Roswell Park Cancer Institute · Not applicable, Interventional, and Prevention

How we know

Updated Oct 16, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Carcinoma, Renal Cell by Roswell Park Cancer Institute — 1 open to participants now, 2 under way, none of them phase 3. Carcinoma, Renal Cell · Roswell Park Cancer Institute.

Planned enrollment
6th of 12
20 · median 20
Started
2026
the only one that year
No phase
7 of 12
1 open now
Registered
12th of 12
by date

Among the 12 studies in Carcinoma, Renal Cell by Roswell Park Cancer Institute, this one is the 6th largest by planned enrollment, is the only one that started in 2026, is one of 7 with no phase, and was the 12th registered.

Carcinoma, Renal Cell

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

1 of the 12 studies in Carcinoma, Renal Cell by Roswell Park Cancer Institute is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 308 Carcinoma, Renal Cell studies recruiting now, 255 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Carcinoma, Renal Cell by Roswell Park Cancer Institute, or all of them as a file.
02

Study summary

This clinical trial compares two different weight-loss programs, daily continuous calorie energy reduction (CER) versus (vs.) 5:2 intermittent fasting (IF), in preventing progression of kidney (renal) cancer among patients with one or more small renal masses (SRM) undergoing active surveillance (AS). Kidney cancer patients tend to have changes in metabolism that may increase body weight, but weight-loss strategies that work for best for these patients are unknown. The CER program requires a set daily limit for calories. The IF program requires fasting for 2 days a week and normal eating for the remaining 5 days. Both will include self-monitoring with interventionist feedback. This trial may help researchers determine whether the IF program works better than the CER program in improving weight loss, physical health, and/or reducing the risk of kidney cancer progression among patients with small renal masses undergoing AS

Read the detailed description

PRIMARY OBJECTIVES:

I. Adapt two evidence-based behavioral weight loss intervention programs (IF and CER) with a goal to cause weight loss in SRM patients on AS.

II. Determine the feasibility of the two intervention programs (IF and CER).

SECONDARY OBJECTIVE:

I. Measure, compare and explore preliminary effect sizes of IF vs. CER on body weight, diet, body composition, tumor growth, and rates of clinical progression and invasive treatment conversion

03

Conditions studied

  • Renal Cell Carcinoma (RCC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • English speaking
  • SRM patient with -confirmed RCC who are initiating or already on AS
  • Age 18 years or older
  • (BMI) ≥ 25 kg/m\^2
  • No medical problems that might contraindicate participation in a behavioral weight reduction program containing an exercise component
  • No weight loss medication in the past 3 months
  • Not pregnant or lactating
  • No more than 5% body weight loss in the past 3 months
  • No bariatric surgery in the last 10 years

Exclusion criteria

Exclusion Criteria:

  • Non-English speaking
  • Less than 18 years old
  • \< 25 kg/m\^2
  • Medical problems that might contraindicate participation in a behavioral weight reduction program containing an exercise component
  • On weight loss medication in the past 3 months
  • Pregnant or lactating
  • More than 5% body weight loss in the past 3 months
  • Bariatric surgery in the last 10 years
  • Any condition which in the Investigator's opinion deems the participant an unsuitable candidate to receive study drug
  • Unwilling or unable to follow protocol requirements
  • Received an agent within 30 days prior to enrollment
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Active comparator
    Arm I - CER Program

    Patients complete the CER program for 6 months. The CER intervention will be adapted to renal cell carcinoma patients on active surveillance

    Other: Continuous Energy Restriction (CER)

  • Active comparator
    Arm II - IF Program

    Patients will complete the IF program for 6 months. The IF arm will mirror the CER arm with the exception that IF additionally include 2 fasting days per week during which participants will be instructed to eat one 500-600kcal meal per fasting day.

    Other: Intermittent Fasting

Interventions

  • OtherIntermittent Fasting

    The IF intervention will instruct participants how to fast safely, how to conduct a 5:2 fast, and encourage moderate physical activity. Self-monitoring with interventionist feedback will also be included

  • OtherContinuous Energy Restriction (CER)

    Lessons about lowering caloric intake each day and moderate physical activity with self-monitoring and interventionist feedback

06

What researchers measure

Primary outcomes

  1. Participation Rate

    This will assess the rate of eligible persons who enroll after invitation and the mean proportion of intervention components completed by arm and participant

    Time frame: At 6 months

Secondary outcomes

  1. Change in tumor size

    Will be assessed based on radiologic imaging. Within-group differences between baseline and 6 months will be examined using paired t-tests or Wilcoxon signed-rank tests for continuous variables, and McNemar's test for categorical variables.

    Time frame: At baseline and at 6 months

  2. Rate of clinical progression

    defined based on radiologic tumor size (\> 4 cm), stage (\> cT1a) and growth rate (\> 5 mm/year for \< 3 cm size; \> 3 mm/year for tumor size \> 3 cm), in addition to biopsy histology (high grade or unclassified renal cell carcinoma histologic subtype) and patient symptomology (bleeding or paraneoplastic symptoms/signs attributable to the tumor), as per the International Consultation for Urologic Disease guidelines

    Time frame: Up to 6 months

  3. Change in Dietary Intake

    Participants will complete 3 recalls over the phone regarding dietary intake over a prior 24-hour period.

    Time frame: Baseline and 6 months

  4. Change in Body composition

    Will be measured using a body composition monitor, which uses bioelectrical impedance analysis to measure whole body and segmental body composition, including trunk fat..

    Time frame: Baseline and at 6 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2027, 12 months later.

Of 120 non-industry interventional studies with no phase under Carcinoma, Renal Cell, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 114. This study's planned 12 months is below that.

Counting every sponsor, half of 127 studies reached it within 45 months; a quarter within 21 and three quarters within 114.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: start Sep 2026 → Nov 2026, primary completion Sep 2027 → Nov 2027 and completion Sep 2028 → Nov 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2026
First posted
Jul 20, 2026
StartEst.
Nov 1, 2026was Sep 2026
Primary completionEst.
Nov 1, 2027was Sep 2027
CompletionEst.
Nov 1, 2028was Sep 2028
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 1, 2026→Nov 1, 2026
Oct 16, 2026
Primary completion
Sep 1, 2027→Nov 1, 2027
Oct 16, 2026
Study completion
Sep 1, 2028→Nov 1, 2028
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Start date Sep 1, 2026→Nov 1, 2026
    Primary completion Sep 1, 2027→Nov 1, 2027
    Study completion Sep 1, 2028→Nov 1, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07714018
Responsible party
Sponsor
First posted
Jul 20, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Nov 1, 2027 (estimated)
Completion
Nov 1, 2028 (estimated)
Last update
Oct 16, 2026

Study contacts

ASK RPCI
Contact
askroswell@roswellpark.org
1-800-767-9355
Eric Kaufmann
principal investigator · Roswell Park Comprehensive Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion